Properties |
Information |
PhytoCAT-ID |
PhytoCAT-1098 |
Phytochemical name or plant extracts |
Embelin |
PMID |
23425971 |
Literature evidence |
In our previous studies, we have demonstrated that embelin is able to induce the apoptosis of MCF-7 breast cancer cells in a dose-dependent manner. |
IUPAC name |
2,5-dihydroxy-3-undecylcyclohexa-2,5-diene-1,4-dione |
Phytochemicals’ class or type of plant extracts |
Quinone |
Source of phytochemicals or plant Extracts |
Embelia ribes |
|
Geographical availability |
Assam, Bangladesh, Borneo, Cambodia, China South-Central, China Southeast, East Himalaya, Hainan, India, Jawa, Laos, Malaya, Myanmar, Nicobar Is., Philippines, Sri Lanka, Sulawesi, Sumatera, Thailand, Tibet, Vietnam |
Plant parts |
Fruits |
Other cancers |
Breast cancer |
Target gene or protein |
SOD1, ERK1, ERK2, Bax, Bcl-2, XIAP |
Gene or Protein evidence |
Embelin treatment resulted in activation of extracellular signal-regulated kinase (ERK)1/2 and ROS accumulation, which correlated with downregulation of antioxidant protein SOD1 and consumption of redox modulator reduced glutathione in the XIAP-overexpressing cells. Moreover, embelin was demonstrated to promote mitochondrial release of cytochrome C via regulation of Bax and Bcl-2, resulting in the activation of caspase-3 and -9, while no significant changes in the level of caspase-8 were observed.
Embelin primes IBC cells for TRAIL-mediated apoptosis by its direct action on the anti-caspase activity of XIAP and by shifting the cellular redox balance toward oxidative stress-mediated apoptosis. |
Target pathways |
The results have demonstrated that embelin-induced apoptosis of MCF-7 breast cancer cells involves the mitochondrial pathway. |
IC50 |
NA |
Potency |
Moreover, embelin has the potent effect of restraining the cell cycle transition of breast cancer cells to blockade the cell cycle in G2/M phase, therefore altering the progression of the cell cycle to induce apoptosis. |
Cell line/ mice model |
MCF-7, 4T1 |
Additional information |
Embelin, an inhibitor of RANKL-induced NF-κB activation has great potential as a therapeutic agent for osteoporosis and cancer-linked bone loss. |
PubChem ID |
3218 |
Additional PMIDs |
20826545 23425971 22508521 34282169 33069102 12419914 25336399 |
Additional sources of information |
https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:588451-1 |
Safety |
NA |